Search Result

Isoforms Recommended:	IDH2

Results for "

IDH2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATP Synthase (2) Endogenous Metabolite (4) Histone Demethylase (2) Isocitrate Dehydrogenase (IDH) (10) Isotope-Labeled Compounds (1) mTOR (2) Reactive Oxygen Species (2) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (13) Inflammation/Immunology (2) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS06530

IDH2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IDH2 Human Pre-designed siRNA Set A contains three designed siRNAs for IDH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IDH2 Human Pre-designed siRNA Set A IDH2 Human Pre-designed siRNA Set A

HY-RS06531

Idh2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Idh2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Idh2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Idh2 Mouse Pre-designed siRNA Set A Idh2 Mouse Pre-designed siRNA Set A

HY-RS06532

Idh2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Idh2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Idh2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Idh2 Rat Pre-designed siRNA Set A Idh2 Rat Pre-designed siRNA Set A

HY-156158

IDH2R140Q-IN-2	Isocitrate Dehydrogenase (IDH)	Cancer
IDH2 ^R140Q-IN-2 (compound 36) is an an orally active IDH2 ^R140Q inhibitor (IC₅₀: 29 nM). IDH2 ^R140Q-IN-2 reduces D2HG production in TF-1 cell lines expressing mutant IDH2 ^R140Q (IC₅₀: 10 nM). IDH2 ^R140Q-IN-2 suppresses D2HG levels in tumor tissue. IDH2 ^R140Q-IN-2 can be used for research of acute myeloid leukemia (AML) .

HY-146002

IDH2R140Q-IN-1	Isocitrate Dehydrogenase (IDH)	Cancer
IDH2R140Q-IN-1 (compound C6) is a potent inhibitor of IDH2 ^R140Q, with an IC₅₀ of 6.1 nM. IDH2R140Q-IN-1 can be used for the research of acute myeloid leukemia .

HY-18690

Enasidenib Maximum Cited Publications 12 Publications Verification AG-221	Isocitrate Dehydrogenase (IDH)	Cancer
Enasidenib is an oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes, with IC₅₀s of 100 and 400 nM against IDH2 ^R140Q and IDH2 ^R172K, respectively.

HY-18690S

Enasidenib-d6 AG-221-d₆	Isotope-Labeled Compounds	Others
Enasidenib-d₆ (AG-221-d₆)is the deuterium labeledEnasidenib(HY-18690) . Enasidenib is an oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes, with IC₅₀s of 100 and 400 nM against IDH2 ^R140Q and IDH2 ^R172K, respectively ^[2].

HY-15734

AGI-6780 5+ Cited Publications	Isocitrate Dehydrogenase (IDH)	Cancer
AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2 ^R140Q with IC₅₀ of 23±1.7 nM. AGI-6780 is less potent against IDH2 ^WT with IC₅₀ of 190±8.1 nM.

HY-18690A

Enasidenib mesylate Maximum Cited Publications 12 Publications Verification AG-221 mesylate	Isocitrate Dehydrogenase (IDH)	Cancer
Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the *IDH2* mutant enzymes.

HY-131312

LY3410738 Mutant IDH1-IN-6	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC₅₀s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes .

HY-104042

Vorasidenib 3 Publications Verification AG-881	Isocitrate Dehydrogenase (IDH)	Cancer
Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC₅₀ ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K ^[2].

HY-149359

*IHMT-IDH1-053*	Isocitrate Dehydrogenase (IDH)	Cancer
IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible *IDH1-mutant* inhibitor with an IC₅₀ of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC₅₀=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants .

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is a potent, selective mutant *IDH1* inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases .

HY-121736

AGI-12026 AGI-026	Isocitrate Dehydrogenase (IDH)	Neurological Disease
AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma .

HY-100542

D-α-Hydroxyglutaric acid disodium 2 Publications Verification Disodium (R)-2-hydroxyglutarate	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling ^[2] .

HY-113038

D-α-Hydroxyglutaric acid (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling ^[2] .

Glutamine Metabolism Compound Library	917 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 917 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Category	Target	Chemical Structure